This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient
dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355
that can be safely administered to participants with acute leukemia. Part A and Part B are
dose escalation of two schedules in participants with acute leukemia. Parts A and B will
enroll concurrently. Part C is a dose expansion for each schedule in participants with acute
myeloblastic leukemia (AML).